Business
Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A
Oakville, Ontario--(Newsfile Corp. - April 1, 2021) - Cardiol Therapeutics Inc. ( TSX: CRDL ...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&AOakville, Ontario--(Newsfile Corp. - April 1, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) (\"Cardiol\" or the \"Company\"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2020. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.cardiolrx.com.David Elsley, President and Chief Executive Officer of Cardiol, commented: \"2020 was a very exciting year for Cardiol Therapeutics. We made extraordinary progress in our research and clinical development programs, while significantly strengthening our financial position. We are particularly excited about the progress made across our research and development programs supporting the development of CardiolRx™, our pharmaceutically produced extra-strength oral formulation of cannabidiol and lead drug candidate for the treatment of acute inflammatory heart disease.\" \"Notably, receiving Investigational New Drug (\"IND\") approval from the FDA for our Phase II/III study in hospitalized COVID-19 patients with prior history of, or risk factors for cardiovascular disease (\"CVD\"), has presented a unique opportunity to investigate the impact of the cardioprotective properties of CardiolRx on a composite endpoint consisting of one or more of several common significant adverse outcomes in this patient population, including all-cause mortality, requirement for ICU admission and/or ventilatory support, as well as cardiovascular complications, including the development of heart failure, acute myocardial infarction, myocarditis, stroke, or new sustained or symptomatic arrhythmia. We believe successful outcomes from this study will support an emergency use authorization and/or a new drug application and will provide invaluable clinical data with respect to the therapeutic potential of CardiolRx™ in the treatment of other inflammatory heart diseases, including acute myocarditis and heart failure.\" \"Based on the large body of experimental evidence of the anti-inflammatory and cardioprotective properties of cannab...